Given the similar neuroimmune mechanisms of IL-31 in AD and ACD, further studies on the applicability of IL-31 as a marker of ACD- related itch, and its inhibition in therapeutic applications should be investigated. This evidence concerns the gene IL31 and granular corneal dystrophy type II.